Shares in Novocure (NSDQ:NVCR) fell today after the medical device maker missed expectations on Wall Street with its first-quarter results. The St. Helier, N.J.-based company posted a net loss of -$20.7 million, or -23¢ per share, on sales of $52.1 million for the 3 months ended March 31, for bottom-line loss of -14.8% on sales growth […]
Novocure touts top-line data from Ph2 mesothelioma trial
Novocure (NSDQ:NVCR) today touted positive top-line data from its Phase II pilot mesothelioma trial and revealed that it plans to submit a humanitarian device exemption application to the FDA for approval. The St. Helier, N.J.-based company reported that patients who received treatment with its “Tumor Treating Fields” system plus chemotherapy experienced clinically meaningful improvements in overall […]
Novocure misses Q4 EPS by a penny, tops sales estimates
Shares in Novocure (NSDQ:NVCR) rose slightly today in premarket activity after the medical device maker met sales expectations, but missed earnings estimates on Wall Street with its fourth quarter and full-year financial results. The St. Helier, N.J.-based company reeled in losses this quarter, posting -$10.9 million on sales of $53.7 million for the 3 months ended […]
Novocure lands $150m term loan
Novocure (NSDQ:NVCR) has inked a $150 million term loan agreement with Pharmakon Advisors’ investment fund, BioPharma Credit. The St. Helier, N.J.-based company plans to set aside some of the new funds for working capital, as well as pay off its existing $100 million term loan debt. “Novocure is a global oncology company with a proprietary platform […]
Novocure touts quality-of-life analysis for glioblastoma patients treated with Optune-chemo combo
Novocure (NSDQ:NVCR) today touted an analysis published in JAMA Oncology showing that its Optune-temozolomide combination helped newly-diagnosed glioblastoma patients live longer without hurting their quality of life. In a Phase III pivotal trial, researchers found that a higher proportion of patients treated with Optune and temozolomide reported stable or improved quality of life measures compared to those […]
Novocure revenues climb in Q4, FY17 prelims
Novocure (NSDQ:NVCR) shares rose slightly this morning after the cancer-treatment developer reported its preliminary fourth quarter and full-year revenues. The St. Helier, N.J.-based company said it expects to land $53.7 million in net revenue for the fourth quarter of 2017, up 77% from the same period last year. For the full year, Novocure anticipates it will […]
Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients
Novocure (NSDQ:NVCR) touted today the final analysis of a pivotal Phase III trial that evaluated Optune combined with temozolomide in newly-diagnosed glioblastoma patients. The analysis, published today in the Journal of the American Medical Association (JAMA), showed that Novocure’s Optune-temozolomide combo extended overall survival and progression-free survival by 37% compared to temozolomide alone. The drug-device therapy’s benefit […]
Novocure wins FDA nod for pivotal pancreatic cancer trial
The FDA has given Novocure (NSDQ:NVCR) the green light to bring the company’s Tumor Treating Fields tech into a pivotal Phase III pancreatic cancer trial. The 556-patient study is designed to assess the safety and efficacy of Novocure’s TTFields combined with nab-paclitaxel and gemcitabine as a front-line treatment for unresectable locally-advanced pancreatic cancer. Panova III’s primary […]
Court dismisses class action suits against Novocure
Two class action lawsuits filed against Novocure (NSDQ:NVCR) and some of its directors and executives in January were dismissed after the court established that it lacked personal jurisdiction over any of the defendants. In mid-January, Joseph Donahue, Stephen Rosen and Susan Rosen filed two putative class action suits in a New Hampshire court against Novocure, its […]
Novocure nabs reimbursement for Optune in Japan
Novocure (NSDQ:NVCR) shares were up this morning after the Japanese Ministry of Health, Labour and Welfare agreed to reimburse for Optune as a treatment for newly-diagnosed glioblastoma. The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. As a treatment for newly-diagnosed glioblastoma, Novocure combines its device with the […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn